With Another Push From Eisai, Can Arena’s Belviq Be A Blockbuster?
This article was originally published in PharmAsia News
The Japanese pharma has expanded its collaboration with Arena for the obesity treatment Belviq, but the drug is off to a slow start in a market full of non-starters.
You may also be interested in...
The National Business Group on Health survey illustrates the continuing reimbursement challenges faced by the recently introduced obesity drugs Qsymia and Belviq.
Qsymia will launch through certified mail-order pharmacies, but FDA has asked the sponsor to look for ways to expand into the retail space with pharmacies that can meet requirements for distributing patient risk information and keeping track of prescribers.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.